Sophia Genetics, Philippe Menu
Sophia Genetics brings in Philippe Menu as chief medical officer, with a remit of utilizing the company’s data-driven approach to discover new biomarkers for the development of therapeutics.
Prior to Sophia Genetics, Menu had spent eight years at consultancy firm McKinsey where he held the role of associate partner for the last three years and co-led McKinsey Cancer Center, working with clients in the biopharma sector.
Before McKinsey, Menu had attained a PhD in molecular biology, providing him with additional background for his new role at Sophia Genetics.
Jurgi Camblong, CEO and co-founder of the company, stated, “Menu’s background and track record across different sectors of life sciences, including biopharma, will help the execution of new clinical-grade applications. In turn, this will allow the longitudinal monitoring of patients through multi-modal data approaches and the optimization of drug development.”
